Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyeongmi Cheon

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Contemporary Clinical Trials|October 22, 2021
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in menAnna R Giuliano, Timothy Wilkin, Oliver M Bautista, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 2002
Progressive photoreceptor degeneration, outer segment dysplasia, and rhodopsin mislocalization in mice with targeted disruption of the retinitis pigmentosa-1 (Rp1) geneJiangang Gao, Kyeongmi Cheon, Steven Nusinowitz, et al.
Med (New York, N.Y.)|June 21, 2025
A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4)Paul Scott, Benita Ukkonen, Yoseph Caraco, et al.
Vaccines|January 28, 2026
Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health SitesLaura L Hammitt, Ulrike K Buchwald, Jennifer McCauley, et al.
Vaccine|January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Open Forum Infectious Diseases|February 11, 2022
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)Laura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
Vaccine|August 31, 2025
The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assayKyeongmi Cheon, Ulrike K Buchwald, Laura L Hammitt, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 24, 2019
Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver ToxicityYutai Li, Raymond Evers, Michael J Hafey, et al.
Vaccine|March 7, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 studyElmar A Joura, Angels Ulied, Corinne Vandermeulen, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Contemporary Clinical Trials|October 22, 2021
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in menAnna R Giuliano, Timothy Wilkin, Oliver M Bautista, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 2002
Progressive photoreceptor degeneration, outer segment dysplasia, and rhodopsin mislocalization in mice with targeted disruption of the retinitis pigmentosa-1 (Rp1) geneJiangang Gao, Kyeongmi Cheon, Steven Nusinowitz, et al.
Med (New York, N.Y.)|June 21, 2025
A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4)Paul Scott, Benita Ukkonen, Yoseph Caraco, et al.
Vaccines|January 28, 2026
Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health SitesLaura L Hammitt, Ulrike K Buchwald, Jennifer McCauley, et al.
Vaccine|January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Open Forum Infectious Diseases|February 11, 2022
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)Laura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
Vaccine|August 31, 2025
The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assayKyeongmi Cheon, Ulrike K Buchwald, Laura L Hammitt, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 24, 2019
Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver ToxicityYutai Li, Raymond Evers, Michael J Hafey, et al.
Vaccine|March 7, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 studyElmar A Joura, Angels Ulied, Corinne Vandermeulen, et al.
Pageof 2